GlobalData : CPhI Worldwide Frankfurt to feature contributions from Fiona Barry, Peter Shapiro and Bonnie Bain from GlobalData

31 Oct 2019
CPhI Worldwide Frankfurt to feature contributions from Fiona Barry, Peter Shapiro and Bonnie Bain from GlobalData Posted in Pharma

This year's CPhI Worldwide pharma event in Frankfurt, Germany, will take place from 5-7 November 2019. It will feature expert panel discussions moderated by Bonnie (Bornadata) Bain, Global Head and Executive Vice-President of Healthcare Operations & Strategy atGlobalData, alongside Fiona Barry and Peter Shapiro, Editors at PharmSource, a GlobalData product.

Bonnie Bain, Global Head and Executive Vice-President of Healthcare Operations and Strategy, GlobalData

As October nears an end, with UK Prime Minister Boris Johnson's plans for an October 31 Brexit thwarted, and the uncertainty surrounding an election announced on 12 December, the country's future as a hub for pharma research and development (R&D) and manufacturing is unclear. In her talk, 'Brexit and the implications for Pharma - is it a deal or no deal?', Bonnie will examine how Brexit is expected to affect the healthcare sector within and outside the UK, as well as discuss the findings of GlobalData's quarterly industry surveys on Brexit preparedness, in the presentation, 'Brexit and the implications for Pharma - is it a deal or no deal?'.

Bonnie will also share insights into the advances of digital technology and its value to the entire pharma value chain in the talk 'Digital disruption is knocking - is healthcare ready?'. How will key technologies such as AI, blockchain, biosensors, robotics and 3D printing provide opportunities for healthcare in the near-term?

IMAGE Available to Download: Please click here

Fiona Barry
Global Head & Executive Vice President of Healthcare Operations & Strategy, GlobalData

Brexit and the implications for Pharma - is it a deal or no deal?

Tuesday, 5th November, 11:45am - 12:30, World of Pharma Podium

Digital disruption is knocking - is healthcare ready?

Tuesday, 5 November 13:45 - 14:30

Fiona Barry, Editor, PharmSource

Fiona will lead 'Understanding the Cell & Gene Technology Opportunity', a lively panel on the manufacturing and commercialization of advanced therapies. She will be joined by experts from Lonza, Thermo Fisher Scientific, MilliporeSigma, Oxford BioMedica, Paragon Bioservices, Strategy& and ALira Health.

Fiona will also moderate the CPhI Worldwide Media Debate, leading a discussion of the year's most influential trends in pharma with contributors to the CPhI Annual Report including Bikash Chatterjee (President and CSO at Pharmatech Associates), and Dan Stanton (Editor at BioProcess International).

IMAGE Available for Download: Please click here

Fiona Barry

Editor at PharmSource, a GlobalData Company
CPhI Worldwide Media Debate
Tuesday 5th November, 12:00 - 13:00, ClubRaum

Understanding the Cell and Gene Technology Opportunity
Wednesday, 6 November, 10:30 - 11:40, ICSE Theatre

Peter Shapiro, Editor, PharmSource

Peter Shapiro will be kicking off the first morning at CPhI, moderating the panel, 'Exploring Trends in Contract Manufacturing', joined by contributors from Patheon (part of Thermo Fischer Scientific), Catalent, Dr Reddy's, Pharmatech Associates, xCell Strategic Consulting and PharmSource founder and former President Jim Miller.

IMAGE Available to Download: Please click here

Peter Shapiro
Editor at PharmSource a GlobalData Company

Exploring Trends in Contract Manufacturing
Tuesday, 5th November, 10:30 - 11:40, ISCE Theatre

CPhI Annual Report 2019

PharmSource analyst Adam Bradbury provides a number of key insights in the forthcoming CPhI Annual Report 2019, writing that the recent increase in drug approvals and priority review shows the future is bright for the contract manufacturing organization (CMO) industry.

Bradbury commented, 'New drug approvals are on the way up, as the Food and Drug Administration (FDA) approved 11% more innovator therapies in 2018 compared to the previous year, spelling good news for both marketing authorization holders (MAHs) and CMOs. Data also show small and mid-cap pharma companies especially are increasingly turning to outsourcers to manufacture newly approved drugs.'